The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 54, Issue 3, 2005, Pages 314-320

  Jung, Hye Seung ^a   Youn, Byung Soo ^b   Cho, Young Min ^a   Yu, Kang Yeol ^b   Park, Hong Je ^b   Shin, Chan Soo ^a   Kim, Seong Yeon ^a   Lee, Hong Kyu ^a   Park, Kyong Soo ^a  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RESISTIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEMOGLOBIN DETERMINATION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 13844270858     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.05.019     Document Type: Article

References (35)

1. R.S. Ahima, and J.S. Flier Adipose tissue as an endocrine organ Trends Endocrinol. Metab. 11 2000 327 332
2. C.M. Steppan, S.T. Bailey, and S. Bhat The hormone resistin links obesity to diabetes Nature 409 2001 307 312
3. J. Janke, S. Engeli, and K. Gorzelniak Resistin gene expression in human adipocytes is not related to insulin resistance Obes. Res. 10 2002 1 5
4. C.C. Juan, L.C. Au, and V.S. Fang Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids Biochem. Biophys. Res. Commun. 289 2001 1328 1333
5. S. Le Lay, J. Boucher, and A. Rey Decreased resistin expression in mice with different sensitivities to a high-fat diet Biochem. Biophys. Res. Commun. 289 2001 564 567
6. I. Nagaev, and U. Smith Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle Biochem. Biophys. Res. Commun. 285 2001 561 564
7. O. Ukkola Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Eur. J. Endocrinol. 147 2002 571 574
8. D.B. Savage, C.P. Sewter, and E.S. Klenk Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans Diabetes 50 2001 2199 2202
9. J.M. Way, C.Z. Gorgun, and Q. Tong Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor gamma agonists J. Biol. Chem. 276 2001 25651 25653
10. L. Patel, A.C. Buckels, and I.J. Kinghorn Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators Biochem. Biophys. Res. Commun. 300 2003 472 476
11. B.S. Youn, K.Y. Yu, and H.J. Park Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 89 2004 150 156
12. A. Fujinami, H. Obayashi, and K. Ohta Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes Clin. Chim. Acta 339 2004 57 63
13. P.G. McTernan, F.M. Fisher, and G. Valsamakis Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes J. Clin. Endocrinol. Metab. 88 2003 6098 6106
14. J.L. Zhang, Y.W. Qin, and X. Zheng Serum resistin level in essential hypertension patients with different glucose tolerance Diabet. Med. 20 2003 828 831
15. M. Degawa-Yamauchi, J.E. Bovenkerk, and B.E. Juliar Serum resistin (FIZZ3) protein is increased in obese humans J. Clin. Endocrinol. Metab. 88 2003 5452 5455
16. J.H. Lee, J.L. Chan, and N. Yiannakouris Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects J. Clin. Endocrinol. Metab. 88 2003 4848 4856
17. J.V. Silha, M. Krsek, and J.V. Skrha Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance Eur. J. Endocrinol. 149 2003 331 335
18. K. Azuma, F. Katsukawa, and S. Oguchi Correlation between serum resistin level and adiposity in obese individuals Obes. Res. 11 2003 997 1001
19. B. Moon, J.J. Kwan, and N. Duddy Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation Am. J. Physiol. Endocrinol. Metab. 285 2003 E106 E115
20. M. Pravenec, L. Kazdova, and V. Landa Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat J. Biol. Chem. 278 2003 45209 45215
21. R.R. Banerjee, S.M. Rangwala, and J.S. Shapiro Regulation of fasted blood glucose by resistin Science 303 2004 1195 1198
22. M.W. Rajala, S. Obici, and P.E. Scherer Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production J. Clin. Invest. 111 2003 225 230
23. A.J. Wagstaff, and K.L. Goa Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus Drugs 62 2002 1805 1837
24. G. Zhou, R. Myers, and Y. Li Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 108 2001 1167 1174
25. D. Kirpichnikov, S.I. McFarlane, and J.R. Sowers Metformin: an update Ann. Intern. Med. 137 2002 25 33
26. S.A. Phillips, T.P. Ciaraldi, and A.P. Kong Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy Diabetes 52 2003 667 674
27. J.G. Yu, S. Javorschi, and A.L. Hevener The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects Diabetes 51 2002 2968 2974
28. M. Bajaj, S. Suraamornkul, and L.J. Hardies Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients Int. J. Obes. Relat. Metab. Disord. 28 2004 783 789
29. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
30. WHO Western Pacific Region. The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
31. H.B. Hartman, X. Hu, and K.X. Tyler Mechanisms regulating adipocyte expression of resistin J. Biol. Chem. 277 2002 19754 19761
32. N. Shojima, H. Sakoda, and T. Ogihara Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells Diabetes 51 2002 1737 1744
33. H. Fujita, H. Fujishima, and T. Morii Effect of metformin on adipose tissue resistin expression in db/db mice Biochem. Biophys. Res. Commun. 298 2002 345 349
34. H. Hirose, T. Kawai, and Y. Yamamoto Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes Metabolism 51 2002 314 317
35. N. Maeda, M. Takahashi, and T. Funahashi PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2001 2094 2099